Literature DB >> 16508336

Antibodies against four proteins from a Streptococcus pyogenes serotype M1 strain and levels of circulating mannan-binding lectin in acute poststreptococcal glomerulonephritis.

L Skattum1, P Akesson, L Truedsson, A G Sjöholm.   

Abstract

BACKGROUND: Responses against antigens from the potentially nephritogenic Streptococcus pyogenes serotype M1 in patients with acute poststreptococcal glomerulonephritis (AGN) were studied to seek indications of expression of these antigens during the preceding infection. Also, the question was asked whether the complement protein mannan-binding lectin (MBL) is required for development of the hypocomplementemia associated with AGN. Hypothetically, the lectin pathway might trigger the alternative pathway, which is consistently activated in AGN.
METHODS: Antibodies against three proteins associated with M1, M1 protein, streptococcal inhibitor of complement (SIC) and protein H, an IgG-binding protein, were determined by ELISA in 56 children and 17 adults with AGN. Antibodies against streptococcal cysteine proteinase, which is produced by all serotypes of S. pyogenes, were also examined. MBL concentrations were measured in the same 71 patients by a sandwich ELISA.
RESULTS: Increased concentrations of antibodies were found against all four streptococcal proteins, albeit not uniformly distributed between different subgroups of patients. The prevalence of low MBL concentrations (<100 microg/l) including 2 patients with undetectable MBL (<10 microg/l) was similar in AGN (11%) and in controls (16%).
CONCLUSIONS: Our results give evidence of exposure to SIC and protein H in conjunction with AGN. This implies that SIC and protein H and/or cross-reacting proteins may have a role in the pathogenesis of AGN or that streptococci expressing SIC or protein H are nephritogenic for other reasons. The finding of MBL-deficient individuals among the patients demonstrates that MBL is not necessary for the recruitment of complement in AGN. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16508336     DOI: 10.1159/000091745

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  6 in total

1.  Seropositivity for Antibodies to DRS-G, a Virulence Factor from Streptococcus dysgalactiae subsp. equisimilis, Is an Independent Risk Factor for Poststreptococcus Glomerulonephritis and Chronic Kidney Disease in Mumbai, India.

Authors:  Gouri P Hule; Mohan G Karmarkar; Ainslie Cameron; Niwrutti Hase; Uday Khopkar; Preeti R Mehta; Celia L McNeilly; David McMillan; Kadaba S Sriprakash
Journal:  Clin Vaccine Immunol       Date:  2015-06-17

2.  Seroreactivity against streptococcal DRS (distantly related to SIC) protein is a predictor for end-stage renal failure.

Authors:  Virginia A F Boon; James L Munro; George W Kan; James Burnell; Richard Speare
Journal:  Clin Vaccine Immunol       Date:  2008-08-06

Review 3.  Disease manifestations and pathogenic mechanisms of Group A Streptococcus.

Authors:  Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

Review 4.  Autoimmunity in Acute Poststreptococcal GN: A Neglected Aspect of the Disease.

Authors:  Bernardo Rodriguez-Iturbe
Journal:  J Am Soc Nephrol       Date:  2021-02-02       Impact factor: 10.121

5.  Antibodies to group A streptococcal virulence factors, SIC and DRS, increase predilection to GAS pyoderma.

Authors:  Mohan G Karmarkar; Gouri P Hule; Ainslie Cameron; Preeti R Mehta; Uday Khopkar; Niwrutti K Hase; Kadaba S Sriprakash
Journal:  BMC Infect Dis       Date:  2015-03-03       Impact factor: 3.090

6.  Seroprevalence of Streptococcal Inhibitor of Complement (SIC) suggests association of streptococcal infection with chronic kidney disease.

Authors:  Mohan Ganesh Karmarkar; Gouri Pandharinath Hule; Niwrutti Khandu Hase; Preeti Rajeev Mehta; Scott Robert Walter; Kadaba Srinivasa Sriprakash
Journal:  BMC Nephrol       Date:  2013-05-06       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.